



31<sup>st</sup> January 2022

## SomnoMed announces world's first technology enabled oral appliance

**SomnoMed Limited (ASX "SOM", or the Company)**, a leading company in the oral appliance treatment solution for sleep-related breathing disorders and obstructive sleep apnea ("OSA"), is pleased to announce the introduction of the world's first technology-enabled oral appliance <sup>1</sup>.

Whilst reviewing our strategy following the World Sleep Meeting in 2019 and during the early parts of the COVID-19 pandemic in 2020, SomnoMed embarked on a development program to address a key limitation of oral appliance therapy – a lack of objective data.

A large, internally commissioned medical research report highlighted this lack of objective data as a key barrier to prescribing oral appliances. In response, SomnoMed has set out to deliver a technology solution to the world of oral appliances that will provide this data that has only been available with CPAP devices to date.

SomnoMed's aim is to ensure that all treatment stakeholders, including patients, can access overnight data on oral appliance treatment effectiveness. To achieve this, the connected technology will deliver data on both efficacy and compliance, which together determine clinical effectiveness. This collection of powerful, personalized patient data in oral appliance therapy will inform physicians and dentists, every night, about treatment effectiveness for each of their individual patients.

"SomnoMed is extremely proud to bring to the sleep industry true technology that matters to patients and all treatment stakeholders," commented SomnoMed's Managing Director, Mr. Neil Verdal-Austin. "This will empower patients to manage their own OSA treatment with a technology-enabled oral appliance providing measures of both efficacy and compliance. Whilst such data availability is standard for CPAP, having personalised treatment data, shared confidentially between clinicians and patients, is truly a world first for oral appliances," noted Mr. Verdal-Austin.

Further details on the completion of the clinical trial, final steps in the validation process (supplier selection, software validation, docking station functionality), regulatory submissions and likely timing of commercial readiness will be announced on 22<sup>nd</sup> February 2022 when the Company's half yearly results will be released.

**Customer messaging video link:**

<https://somnomed.co/en/dawn-of-a-new-era/>

**Note:**

1. Subject to completing all the final steps in the validation process and all global regulatory submissions.

**This release has been approved by the Board of SomnoMed Limited**

---ends---

**For further information please contact**

**Corporate**

Mr. Neil Verdal-Austin

CEO SomnoMed

+61 406 931 477

Nverdal-austin@somnomed.com

**Investors**

Mr. Craig Sainsbury

Market Eye

+61 428 550 499

[Craig.sainsbury@marketeye.com.au](mailto:Craig.sainsbury@marketeye.com.au)

Ms. Stephanie Ottens

Market Eye

+61 434 405 400

Stephanie.ottens@marketeye.com.au

**About SomnoMed**

SomnoMed is a public company providing treatment solutions for sleep-related breathing disorders including obstructive sleep apnea, snoring and bruxism. SomnoMed was commercialized on the basis of extensive clinical research. Supporting independent clinical research, continuous innovation and instituting medical manufacturing standards has resulted in SomnoDent<sup>®</sup> becoming the state-of-the-art and clinically proven medical oral appliance therapy for more than 675,000 patients in 28 countries. For additional information, visit SomnoMed at <https://somnomed.co/au/>